Q: Which SGLT2 inhibitors have proven cardiovascular mortality benefit in Type 2 Diabetes?

Two SGLT2 inhibitors have demonstrated significant cardiovascular mortality reduction in landmark trials: Empagliflozin (EMPA-REG OUTCOME trial, 2015) — 38% reduction in CV death in T2DM patients with established CVD; Canagliflozin (CANVAS trial, 2017) — 14% reduction in major adverse cardiovascular events (MACE). Additionally, Dapagliflozin (DAPA-HF trial) and Empagliflozin (EMPEROR-Reduced trial) have Class I ESC 2023 recommendations for heart failure with reduced ejection fraction (HFrEF) regardless of diabetes status. ADA 2024 recommends SGLT2 inhibitors as preferred add-on therapy for T2DM patients with established CVD, heart failure, or CKD.

Q: What is the Centor score and how does it guide antibiotic prescribing for sore throat?

The Centor score predicts Group A Streptococcal (GAS) pharyngitis. Score 1 point each for: tonsillar exudate, tender anterior cervical lymphadenopathy, fever >38°C, and absence of cough. Score 0–1: very low GAS probability ( 50%) — immediate antibiotic. First-line: Phenoxymethylpenicillin (Penicillin V) 500 mg QDS × 10 days or Amoxicillin 500 mg TDS × 10 days. Penicillin allergy: Azithromycin 500 mg OD × 5 days. Note: avoid Amoxicillin if EBV/glandular fever suspected — causes maculopapular rash.

Q: What is the post-bronchodilator FEV1/FVC ratio that confirms COPD on spirometry?

GOLD 2024 defines COPD as a post-bronchodilator FEV1/FVC ratio <0.70 (fixed ratio criterion). Pre-bronchodilator measurements can overestimate obstruction and should not be used for diagnosis. After confirming obstruction, GOLD severity staging uses FEV1 % predicted: GOLD 1 (mild) ≥80%; GOLD 2 (moderate) 50–79%; GOLD 3 (severe) 30–49%; GOLD 4 (very severe) <30%. GOLD groups A/B are then assigned based on symptom burden (mMRC/CAT score) and exacerbation history. GOLD A/B: LAMA monotherapy (Tiotropium) first-line. GOLD E (≥2 exacerbations or ≥1 hospitalisation): LAMA + LABA + ICS triple therapy.

Question 1

What CME modules are available on GPManual?

Accepted Answer

GPManual offers 9 interactive CME quiz modules covering: Hypertension Management 2024 (1 credit), Type 2 Diabetes ADA 2024 Update (2 credits), Antibiotic Stewardship in GP (1 credit), Pediatric Fever Management (1 credit), COPD & Asthma GOLD/GINA 2024 (2 credits), AF & Heart Failure ESC 2023 (2 credits), Dermatology: Skin Cancer & Eczema (2 credits), Gastroenterology: H. pylori, IBD & CRC (2 credits), and Neurology: Stroke, TIA & Epilepsy (2 credits). Each module includes key learning points, a multiple-choice quiz with instant feedback and explanations, and a CPD certificate on completion.

Question 2

Are the CME credits from GPManual accepted for PMDC, MRCGP, or MCPS revalidation?

Accepted Answer

GPManual CME modules are designed as self-directed continuing professional development (CPD) activities. The CPD certificate generated on completion is suitable for inclusion in PMDC log books, MRCGP revalidation portfolios, and MCPS Family Medicine CPD records as self-directed learning evidence. The modules are aligned with NICE, ESC, ADA, GOLD, and GINA guidelines. Always check your specific regulatory body's requirements for accepted CPD formats.

Question 3

What is the first-line treatment for Stage 1 hypertension according to ACC/AHA 2017 guidelines?

Accepted Answer

ACC/AHA 2017 defines Stage 1 hypertension as BP ≥130/80 mmHg. For Stage 1 HTN without cardiovascular risk factors, lifestyle modification alone is recommended for 3–6 months before starting medication. For Stage 1 HTN with established CVD or 10-year ASCVD risk ≥10%, pharmacotherapy is initiated alongside lifestyle changes. First-line drug choices: ACE inhibitor or ARB for diabetic or CKD patients; CCB (amlodipine) or thiazide-like diuretic (chlorthalidone) for non-diabetic patients under 55; CCB or thiazide preferred for Black patients. Target BP <130/80 mmHg for most patients.

Question 4

Which SGLT2 inhibitors have proven cardiovascular mortality benefit in Type 2 Diabetes?

Accepted Answer

Two SGLT2 inhibitors have demonstrated significant cardiovascular mortality reduction in landmark trials: Empagliflozin (EMPA-REG OUTCOME trial, 2015) — 38% reduction in CV death in T2DM patients with established CVD; Canagliflozin (CANVAS trial, 2017) — 14% reduction in major adverse cardiovascular events (MACE). Additionally, Dapagliflozin (DAPA-HF trial) and Empagliflozin (EMPEROR-Reduced trial) have Class I ESC 2023 recommendations for heart failure with reduced ejection fraction (HFrEF) regardless of diabetes status. ADA 2024 recommends SGLT2 inhibitors as preferred add-on therapy for T2DM patients with established CVD, heart failure, or CKD.

Question 5

What is the Centor score and how does it guide antibiotic prescribing for sore throat?

Accepted Answer

The Centor score predicts Group A Streptococcal (GAS) pharyngitis. Score 1 point each for: tonsillar exudate, tender anterior cervical lymphadenopathy, fever >38°C, and absence of cough. Score 0–1: very low GAS probability (<10%) — no antibiotic, no throat swab. Score 2–3: moderate probability (30–50%) — consider throat swab; delayed antibiotic prescription. Score 4: high probability (>50%) — immediate antibiotic. First-line: Phenoxymethylpenicillin (Penicillin V) 500 mg QDS × 10 days or Amoxicillin 500 mg TDS × 10 days. Penicillin allergy: Azithromycin 500 mg OD × 5 days. Note: avoid Amoxicillin if EBV/glandular fever suspected — causes maculopapular rash.

Question 6

What are the 4 pillars of heart failure with reduced ejection fraction (HFrEF) therapy according to ESC 2023?

Accepted Answer

ESC 2023 recommends 4 disease-modifying drug classes for HFrEF (EF <40%), all with Class I evidence for mortality reduction: (1) ACE inhibitor/ARB/ARNI — Ramipril, Sacubitril/Valsartan (Entresto); (2) Beta-blocker — Bisoprolol, Carvedilol, Metoprolol succinate; (3) Mineralocorticoid receptor antagonist (MRA) — Spironolactone 25–50 mg or Eplerenone; (4) SGLT2 inhibitor — Dapagliflozin 10 mg OD or Empagliflozin 10 mg OD (Class I regardless of diabetes status). All 4 should be initiated and up-titrated as tolerated. Diuretics (furosemide) are used for symptom relief of congestion but have no mortality benefit. ICD is indicated if EF remains <35% after ≥3 months of optimal medical therapy.

Question 7

What is the post-bronchodilator FEV1/FVC ratio that confirms COPD on spirometry?

Accepted Answer

GOLD 2024 defines COPD as a post-bronchodilator FEV1/FVC ratio <0.70 (fixed ratio criterion). Pre-bronchodilator measurements can overestimate obstruction and should not be used for diagnosis. After confirming obstruction, GOLD severity staging uses FEV1 % predicted: GOLD 1 (mild) ≥80%; GOLD 2 (moderate) 50–79%; GOLD 3 (severe) 30–49%; GOLD 4 (very severe) <30%. GOLD groups A/B are then assigned based on symptom burden (mMRC/CAT score) and exacerbation history. GOLD A/B: LAMA monotherapy (Tiotropium) first-line. GOLD E (≥2 exacerbations or ≥1 hospitalisation): LAMA + LABA + ICS triple therapy.

GP CME Modules — Medical Quizzes & Exam Prep

Hypertension Management 2024

Type 2 Diabetes: 2024 Update

Antibiotic Stewardship in GP

Pediatric Fever Management

COPD & Asthma: GOLD & GINA 2024

AF & Heart Failure: ESC 2023

Dermatology: Skin Cancer & Eczema

Gastroenterology: H. pylori, IBD & CRC

Neurology: Stroke, TIA & Epilepsy